INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPRNewsWire · Oct 15, 2026
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 WeeksZacks Investment Research · Oct 14, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAGlobeNewsWire · Oct 13, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPRNewsWire · Oct 8, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAGlobeNewsWire · Oct 6, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPRNewsWire · Oct 1, 2026Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.65 | -$0.69 | Miss |
| May 13, 2026 | -$0.60 | -$0.64 | Miss |
| Mar 2, 2026 | -$0.54 | -$0.57 | Miss |
| Nov 5, 2025 | -$0.50 | -$0.50 | Beat |
| Aug 14, 2025 | -$0.53 | -$0.47 | Beat |
| May 8, 2025 | -$0.49 | -$0.47 | Beat |